Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the drug
lenalidomide (Revlimid, lenalidomide) that can be given with Rituxan® (rituximab) in the
treatment of relapsed mantle cell lymphoma. The safety and effectiveness of this combination
treatment will also be studied in both mantle cell lymphoma and diffuse large B-cell
non-Hodgkin's lymphoma, transformed large cell lymphoma, and/or Grade 3 follicular lymphoma
(follicular cleaved large cell lymphoma or follicular non-cleaved large cell lymphoma).